The rising prevalence of hyperlipidemia, increasing burden of cardiovascular diseases, and growing awareness of cholesterol management are driving demand for hypolipidemic drugs worldwide. However, the market also faces several challenges. Patent expirations of blockbuster drugs, pricing pressure from generic alternatives, high costs associated with novel lipid-lowering therapies, and...